source
- Replimune will again submit its melanoma drug for approvalThird time’s the charm? Replimune announced Friday that it will submit its advanced melanoma drug RP1 for FDA review after two prior rejections. It said it has had new discussions with ...Endpoints · 2mo ago↗ source
- Agios ends development of tebapivat in low-risk MDS following subpar resultsAgios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data. The biotech’s pyruv…Endpoints · 2mo ago↗ source
- Allogene CEO to step down; Agios drug fails key testDavid Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.